Robert Califf has resigned himself to the fact that the US Food and Drug Administration’s strategy of waging a full-frontal assault on misinformation has to change.
Hard Truths About Mistruths: US FDA’s Califf Switching Gears On Misinformation Fight
Fighting misinformation likely will not be successful, the FDA commissioner concedes, but stakeholders should join the campaign to increase the dissemination of truthful information.
More from Marketing & Advertising
More from Compliance
Now that one of the most controversial pharma M&As of 2024 has closed, the Pink Sheet looks at whether overtures to concerned customers and extended prenotification discussions helped Novo and Catalent seal the deal.
Viatris’ oral finished dose manufacturing facility in Indore, India, was slapped with a US Food and Drug Administration import alert and warning letter.
Final guidance on communicating scientific information on unapproved uses (SIUU) allows firm-generated presentations to be based on sources other than reprints, but says communications based on nonscientific content are not protected from enforcement.